Stocksigma LogoStocksigma Logo

Marksans Pharma Posts Record Q2FY27 Results With 48% EBITDA Surge

Marksans Pharma reported a 30.5% YoY rise in consolidated operating revenue to Rs. 940.2 cr in Q2FY27, driven by strong growth in UK & Europe (+64.9% YoY

Marksans Pharma Posts Record Q2FY27 Results With 48% EBITDA Surge

Marksans Pharma Ltd 路 Press Release 路 04 Nov 2026, 7:12 pm

Marksans Pharma Posts Record Q2FY27 Results With 48% EBITDA Surge Marksans Pharma reported a 30.5% YoY rise in consolidated operating revenue to Rs. 940.2 cr in Q2FY27, driven by strong growth in UK & Europe (+64.9% YoY to Rs. 404.6 cr) and the US (+8.7% YoY to Rs. 420.9 cr). EBITDA grew 48.3% YoY to Rs. 214.3 cr with margins expanding 274 bps to 22.8%. PAT rose 44.8% YoY to Rs. 143.5 cr. In H1FY27, PAT surged 92.5% YoY to Rs. 302.9 cr, operating cash flow jumped 4.3x to Rs. 322 cr, and net cash stood at Rs. 1,095 cr.

Original exchange filing (PDF)

More announcements from Marksans Pharma Ltd

All Marksans Pharma Ltd announcements